Original Article
Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Cirrhosis and Splanchnic Vein Thrombosis
Abstract
Objective: The incidence of splanchnic vein thrombosis (SVT) is reported to be <25 times lower than that of deep vein thrombosis and pulmonary emboli, which occur in 70 to 270/100,000 cases in the general population. Current guidelines recommend initial treatment with therapeutic low-molecular-weight heparin followed by a transition to a vitamin K antagonist (VKA) or a direct oral anticoagulant (DOAC) in patients with cirrhosis who develop SVT without severe liver dysfunction. This, however, is based on observational data. This study aimed to evaluate the efficacy and safety of anticoagulant therapy in patients with cirrhosis who present with SVT and receive either a DOAC or a VKA.Methods: This multicenter retrospective cohort study was conducted from December 2021 to November 2022. Patients between the ages of 18 and 75 years with cirrhosis and acute SVT who received either a VKA or a DOAC between July 2019 and July 2021 were eligible for inclusion. The primary outcome was the efficacy of treatment, defined as a new thrombotic event. The secondary outcome was the safety of treatment, defined as the development of major bleeding. Readmission data were followed up at 6 and 10 months. Bivariate analysis was conducted to assess the relationship between the medication groups and each outcome and summarized as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was set at 5% for all of the comparisons.
Results: A total of 80 patients from 50 hospitals were included in this study. Sixty-one patients (59.02% male) received DOACs and 19 (57.89% male) received a VKA. Of the patients who received DOACs, 41 (67.21%) received apixaban, one (1.64%) received dabigatran, and 19 (31.15%) received rivaroxaban. The results from the bivariate analysis revealed no significant differences between DOACs and warfarin for both the efficacy (OR 1.46, 95% CI 0.44–4.84, P = 0.53) and safety outcomes (OR 1.03, 95% CI 0.04–26.43, P = 1) at 10 months.
Conclusions: The use of DOACs in patients with cirrhosis who present with SVT may be efficacious and safe compared with warfarin. The findings from our study may inform power analyses for well-conducted randomized trials to confirm these findings.
Posted in: Liver Disease8
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med 2015;175:1474–1480.
2. Valeriani E, Riva N, Di Nisio M, et al. Splanchnic vein thrombosis: current perspectives. Vasc Health Risk Manag 2019;15:449–461.
3. Valeriani E, Di Nisio M, Riva N, et al. Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood 2021;137:1233–1240.
4. Di Nisio M, Valeriani E, Riva N, et al. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost 2020;18: 1562–1568.
5. Sogaard KK, Darvalics B, Horvath-Puho E, et al. Survival after splanchnic vein thrombosis: a 20-year nationwide cohort study. Thromb Res 2016;141:1–7.
6. Kawata E, Siew DA, Payne JG, et al. Splanchnic vein thrombosis: clinical manifestations, risk factors, management, and outcomes. Thromb Res 2021;202:90–95.
7. Mantaka A, Augoustaki A, Kouroumalis EA, et al. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 2018;31:315–329.
8. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44:1039–1046.
9. Delahousse B, Labat-Debelleix V, Decalonne L, et al. Comparative study of coagulation and thrombin generation in the portal and jugular plasma of patients with cirrhosis. Thromb Haemost 2010;104:741–749.
10. Menichelli D, Ronca V, Di Rocco A, et al. Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis. Eur J Clin Invest 2021;51:e13397.
11. De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2017;37: 694–699.
12. Davis KA, Joseph J, Nisly SA. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. J Thromb Thrombolysis 2020;50:457–461.
13. Intagliata NM, Henry ZH, Maitland H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 2016;61:1721–1727.
14. Serrao A, Merli M, Lucani B, et al. Outcomes of long-term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis. Eur J Clin Invest 2021;51:e13356.
15. HumJ, Shatzel JJ, Jou JH, et al. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol 2017;98:393–397.
16. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg 2014;12:1500–1524.
17. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799–808.
18. Tripodi A, Mannucci PM.The coagulopathy of chronic liver disease. N Engl J Med2011;365: 147–156.
